Physician profile
Katherine J Baxter
NPI 1346583028
$1,684.09
in general payments reported to CMS, 2019-2025
11 companies · $50.56 in 2025
The $50.56 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.35 · 2022: $75.89 · 2023: $298 · 2024: $1,244 · 2025: $50.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,017 · Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,016.92 |
| Food and Beverage | $575.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,294.88 | 2022-2024 | Da Vinci Surgical System |
| Smith+Nephew, INC. | $74.91 | 2023 | Stravix Pl, Collagenase Santyl |
| Kci USA, INC. | $66.70 | 2022-2023 | Promogran Prisma, Activ.A.C. |
| Baxter Healthcare | $58.57 | 2023 | Perclot |
| Tela Bio, INC. | $36.50 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Medical Device Business Services, INC. | $36.46 | 2025 | Echelon Flex |
| Ethicon US, LLC | $33.49 | 2024 | Harmonic, Enseal, Echelon Flex |
| Integra Lifesciences Corporation | $29.45 | 2021-2025 | Cytal |
| Genmab U.S., INC. | $19.47 | 2023 | Tivdak |
| Glaxosmithkline, LLC. | $18.88 | 2023 | Jemperli, Zejula |
| Mimedx Group, INC. | $14.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.